세계의 심장 부정맥 모니터링 기기 시장 예측 : 제품 유형, 용도, 최종 사용자, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Cardiac Arrhythmia Monitoring Devices Market is accounted for $8.93 billion in 2025 and is expected to reach $16.02 billion by 2032 growing at a CAGR of 8.7% during the forecast period. Cardiac arrhythmia monitoring devices are specialized instruments used to identify and document arrhythmias, or irregular heart rhythms. To diagnose and treat conditions like bradycardia, tachycardia, and atrial fibrillation, these devices are essential. Common varieties that track the electrical activity of the heart either continuously or sporadically include Holter monitors, event recorders, and implantable loop recorders. In order to improve patient outcomes and lower the risk of complications like stroke or heart failure, these monitors assist doctors in determining the frequency and severity of arrhythmias, guiding treatment decisions, and tracking the efficacy of therapies by providing real-time or stored data.

According to the American Heart Association (AHA), atrial fibrillation (AF)-the most common sustained arrhythmia-is projected to affect approximately 2.7 to 6.1 million people in the U.S. in recent years, rising to ≈12.1-15.9 million by 2050, representing a lifetime risk of ~37% in those aged 55 and older.

Market Dynamics:

Driver:

Increasing heart arrhythmia prevalence

The prevalence of cardiac arrhythmias, especially atrial fibrillation (AF), is rising in both developed and developing nations. The American Heart Association estimates that between 2.7 and 6.1 million Americans suffer from AF, and by 2050, that figure is predicted to increase to between 12.1 and 15.9 million. It is estimated that over 33.5 million people worldwide suffer from AF. The main causes of this increasing burden are sedentary lifestyles, obesity, diabetes, and hypertension. Continuous or long-duration monitoring technologies are becoming more and more necessary because arrhythmias are often asymptomatic and intermittent, making them difficult to detect. Moreover, the market for implantable and ambulatory cardiac monitoring devices that provide precise and extended rhythm tracking capabilities is directly driven by this demand.

Restraint:

Expensive equipment and monitoring services

The high cost of cardiac arrhythmia monitoring devices, both initially and over time, is one of the biggest obstacles to their widespread adoption. Mobile cardiac telemetry (MCT) systems and implantable loop recorders (ILRs) can be costly, particularly when you include the price of device implantation, data interpretation, and ongoing subscription-based monitoring services. In low- and middle-income nations with limited health insurance coverage and tight healthcare budgets, these expenses may be unaffordable. Co-pays and deductibles can discourage patients from choosing advanced monitoring, even in developed nations, especially if their symptoms are mild or sporadic. Additionally, this cost burden limits market expansion and prevents patients, particularly those who are elderly or have low incomes, from having access to ongoing monitoring.

Opportunity:

Integration of big data analytics and artificial intelligence (AI)

Arrhythmia monitoring devices that incorporate AI and machine learning algorithms are creating revolutionary opportunities. By evaluating intricate ECG patterns, lowering false positives and negatives, and delivering real-time alerts, artificial intelligence (AI) can greatly improve the accuracy of arrhythmia detection. Based on trends in patient data over time, predictive analytics can also predict the risk of arrhythmias, allowing for earlier intervention and better results. Furthermore, cloud-based platforms make it possible for healthcare systems to effectively store, analyze, and share enormous amounts of ECG data. AI-powered cardiac monitors are positioned as a major growth frontier as the technology becomes more reliable and validated through clinical trials.

Threat:

Risks to cybersecurity and device vulnerabilities

The prevalence of cloud platforms, Bluetooth, and remote data transmission has made cardiac monitoring devices more susceptible to cybersecurity attacks. Serious ethical, legal, and financial repercussions may result from any breach involving patient data. More importantly, if an implanted or wearable device is compromised, it may impact patient safety as well as privacy, particularly if clinical decisions are being made using real-time data. The threat posed by increasingly sophisticated cyber attacks is growing, even though many nations have laws in place. These days, it is expected of device manufacturers to make significant investments in post-market surveillance and cybersecurity frameworks, which raises the cost and complexity. Moreover, public trust could be severely damaged, and a brand's reputation severely damaged, by a well-publicized security breach or system failure.

Covid-19 Impact:

The COVID-19 pandemic affected the market for cardiac arrhythmia monitoring devices in a variety of ways, most of which were favorable. The crisis greatly sped up the adoption of telehealth and remote patient monitoring (RPM) systems, even though initial in-person clinic visits, elective procedures, and supply chain disruptions temporarily slowed device installations and diagnostics. Demand for wearable and ambulatory arrhythmia monitors that could send real-time data from patients' homes increased as hospitals placed a higher priority on minimizing patient exposure and managing chronic conditions outside of clinical settings. Additionally, myocarditis and arrhythmias are among the post-COVID cardiac complications that require monitoring, which emphasizes the importance of continuous ECG monitoring.

The holter monitors segment is expected to be the largest during the forecast period

The holter monitors segment is expected to account for the largest market share during the forecast period, driven by their cost-effectiveness, dependability, and broad clinical adoption. By providing continuous ECG monitoring, usually for 24 to 48 hours, these portable devices enable medical professionals to identify asymptomatic or intermittent arrhythmias that might go undetected during standard ECGs. Bradycardia, atrial fibrillation, and premature ventricular contractions can all be detected with Holter monitors. Even though more sophisticated options like MCT and implantable devices are becoming popular for particular patient groups, they still dominate the market because of their solid track record, extensive reimbursement coverage, and integration into cardiology workflows worldwide.

The diagnostic centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diagnostic centers segment is predicted to witness the highest growth rate. Diagnostic centers are quickly becoming the end-user channel with the fastest rate of growth for cardiac arrhythmia monitoring devices. These centers provide a wide range of ambulatory ECG services, such as mobile telemetry systems, Holter monitors, and event recorders, to identify asymptomatic or intermittent arrhythmias that might not be picked up by brief clinical testing. Furthermore, diagnostic centers appeal to both doctors and patients looking for effective cardiac evaluations because they offer a combination of convenience, cutting-edge diagnostic tools, and outpatient access.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, propelled by its sophisticated healthcare system, high incidence of heart conditions like atrial fibrillation, and robust uptake of cutting-edge technologies. The presence of significant market players like Medtronic, GE Healthcare, and iRhythm Technologies, as well as favorable reimbursement policies and broad access to diagnostic services, all contribute to the region's advantages. Further solidifying the market position in the United States and Canada are the integration of AI-based ECG analysis, the growing use of remote patient monitoring, and growing awareness of early arrhythmia detection. Moreover, North America is the leading region in arrhythmia monitoring revenue and innovation due to its technological, clinical, and financial advantages.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR. A growing burden of cardiovascular diseases, rising healthcare costs, and increased awareness of early cardiac diagnostics in nations like China, India, Japan, and South Korea are all contributing factors to this fast growth. Strong government initiatives to update healthcare infrastructure, increased use of wearable and remote monitoring technologies, and increased access to healthcare services are all happening in the region. Additionally, Asia-Pacific is the most dynamic and rapidly changing market for arrhythmia monitoring devices worldwide, and this is further supported by the region's large, aging population and the growing availability of reasonably priced cardiac monitoring solutions.

Key players in the market

Some of the key players in Cardiac Arrhythmia Monitoring Devices Market include Boston Scientific, Koninklijke Philips N.V, Spacelabs Healthcare Inc., Medtronic PLC, Welch Allyn, GE Healthcare, BioTelemetry, Inc., Abbott Laboratories, iRhythm Technologies Inc., Biotronik Inc, Applied Cardiac Systems, Inc., Fukuda Denshi Co. Ltd., AliveCor Inc., Nihon Kohden Corporation and Schiller AG.

Key Developments:

In April 2025, Medtronic plc announced a strategic agreement to distribute the advanced Dragonfly(TM)* pancreaticobiliary system from Dragonfly Endoscopy, Inc. in the United States. This innovative platform introduces significant enhancements in pancreaticobiliary endoscopy - a field where procedural standards have remained largely unchanged for decades.

In March 2025, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS(TM) Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

In January 2025, GE HealthCare Technologies Inc. signed a seven-year agreement with Sutter Health to provide AI-powered medical technology and software upgrades to the California nonprofit health system, the companies. The agreement is expected to generate $1 billion in revenue over the span of the partnership, GE Healthcare said. It marks one of the largest deals for the medical technology company since the firm was spun off from General Electric Co. two years ago.

Product Types Covered:

• ECG Monitors
• Mobile Cardiac Telemetry Monitors (MCT)
• Implantable Cardiac Monitors
• Holter Monitors
• Event Monitors
• Other Product Types

Applications Covered:

• Bradycardia
• Tachycardia
• Premature Contractions
• Atrial Fibrillation (A.F)
• Conduction Disorders
• Other Applications

End Users Covered:

• Hospitals and Clinics
• Diagnostic Centers
• Ambulatory Surgical Centers
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cardiac Arrhythmia Monitoring Devices Market, By Product Type

• 5.1 Introduction
• 5.2 ECG Monitors
  • 5.2.1 Resting ECG Devices
  • 5.2.2 ECG Stress Test Devices
• 5.3 Mobile Cardiac Telemetry Monitors (MCT)
• 5.4 Implantable Cardiac Monitors
• 5.5 Holter Monitors
• 5.6 Event Monitors
• 5.7 Other Product Types

6 Global Cardiac Arrhythmia Monitoring Devices Market, By Application

• 6.1 Introduction
• 6.2 Bradycardia
• 6.3 Tachycardia
  • 6.3.1 Atrial Tachycardia
  • 6.3.2 Ventricular Tachycardia
• 6.4 Premature Contractions
• 6.5 Atrial Fibrillation (A.F)
• 6.6 Conduction Disorders
• 6.7 Other Applications

7 Global Cardiac Arrhythmia Monitoring Devices Market, By End User

• 7.1 Introduction
• 7.2 Hospitals and Clinics
• 7.3 Diagnostic Centers
• 7.4 Ambulatory Surgical Centers
• 7.5 Homecare Settings
• 7.6 Other End Users

8 Global Cardiac Arrhythmia Monitoring Devices Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Boston Scientific
• 10.2 Koninklijke Philips N.V
• 10.3 Spacelabs Healthcare Inc.
• 10.4 Medtronic PLC
• 10.5 Welch Allyn
• 10.6 GE Healthcare
• 10.7 BioTelemetry, Inc.
• 10.8 Abbott Laboratories
• 10.9 iRhythm Technologies Inc.
• 10.10 Biotronik Inc
• 10.11 Applied Cardiac Systems, Inc.
• 10.12 Fukuda Denshi Co. Ltd.
• 10.13 AliveCor Inc.
• 10.14 Nihon Kohden Corporation
• 10.15 Schiller AG